Global Biopsy Devices Market Size and Forecast (2025–2033)
The Global Biopsy Devices Market is projected to grow from US$ 2.43 billion in 2024 to US$ 4.02 billion by 2033, registering a CAGR of 5.75% during 2025–2033. This steady expansion reflects the rising global cancer burden, growing demand for personalized medicine, and increasing preference for minimally invasive diagnostic procedures.
Biopsy devices play a pivotal role in modern medicine by enabling tissue extraction for pathological analysis. They are essential for early detection, disease classification, and treatment planning—particularly in oncology. As healthcare systems prioritize early diagnosis and precision-based therapies, biopsy technologies are becoming increasingly sophisticated, accurate, and patient-friendly.
Download Free Sample Report:https://www.renub.com/request-sample-page.php?gturl=biopsy-devices-market-key-players-analysis-p.php
Market Overview: The Role of Biopsy Devices
Biopsy devices are medical instruments designed to collect tissue samples for laboratory examination. They are widely used in diagnosing:
- Cancer
- Infectious diseases
- Autoimmune disorders
- Inflammatory conditions
Key biopsy categories include:
- Needle biopsy devices (fine-needle aspiration and core needle systems)
- Punch biopsy instruments (commonly used in dermatology)
- Surgical biopsy tools (for deeper or extensive tissue sampling)
Fine-needle and core needle biopsies enable minimally invasive sampling with minimal disruption to surrounding healthy tissue. Technological advancements have significantly improved sampling precision, imaging integration, and patient comfort.
As innovations continue to reduce procedure time, improve diagnostic yield, and enhance safety, biopsy devices remain indispensable in clinical practice.
Rising Global Cancer Prevalence
Key Drivers of Market Growth
The increasing incidence of cancer worldwide is one of the strongest growth drivers. Early-stage diagnosis significantly improves survival outcomes, and biopsy procedures are fundamental in confirming malignancies and guiding targeted therapies.
As awareness campaigns, screening programs, and diagnostic infrastructure expand globally, biopsy volumes are rising correspondingly.
Shift Toward Minimally Invasive Diagnostics
Healthcare providers and patients alike prefer minimally invasive techniques that:
- Reduce hospital stays
- Minimize scarring
- Lower infection risks
- Shorten recovery times
Needle-based biopsy systems have gained significant traction due to their safety and efficiency, supporting strong market growth.
Growth of Personalized Medicine
Personalized treatment strategies require molecular and histopathological analysis of tissue samples. Biopsy devices enable the extraction of high-quality specimens necessary for genetic profiling, immunohistochemistry, and biomarker testing—critical components of precision oncology.
Leading Biopsy Device Companies & Profiles
Cardinal Health, Inc.
Established: 1971
Headquarters: United States
Cardinal Health supplies a broad portfolio of medical and surgical products, including biopsy instruments. With a strong distribution network serving healthcare facilities nationwide, the company plays a critical role in ensuring accessibility of diagnostic tools. Its operational scale supports timely delivery and consistent supply chain reliability.
Hologic, Inc.
Established: 1985
Headquarters: United States
Hologic specializes in medical imaging, diagnostics, and surgical systems. Its breast imaging and biopsy solutions are widely recognized, particularly in women’s health diagnostics. Through direct sales channels and distributor networks, Hologic maintains strong global reach across Europe, the Americas, and Asia-Pacific.
Danaher Corporation
Established: 1984
Headquarters: United States
Danaher operates across biotechnology, diagnostics, and life sciences. Its portfolio includes advanced laboratory and genomic tools that complement biopsy-driven diagnostics. The company’s presence across the Americas, Europe, Middle East, Africa, and Asia-Pacific reinforces its competitive strength.
Becton, Dickinson and Company
Established: 1897
Headquarters: United States
BD manufactures a broad range of medical devices, laboratory instruments, and diagnostic systems. Its biopsy and sampling technologies are integrated into hospital and clinical workflows worldwide. With manufacturing facilities across multiple continents, BD benefits from strong global production capabilities.
Boston Scientific Corporation
Established: 1979
Headquarters: United States
Boston Scientific develops devices across various interventional specialties. Its biopsy-related solutions serve gastroenterology, pulmonology, and interventional radiology markets. The company maintains manufacturing operations in multiple global locations and distributes products through both direct and distributor networks.
Medtronic plc
In April 2024, Medtronic introduced ColonPRO software for its GI Genius™ intelligent endoscopy platform. The AI-powered system enhances colorectal polyp detection and supports improved diagnostic accuracy during endoscopic procedures.
Olympus Corporation
In October 2025, Olympus launched SecureFlex, a single-use fine needle biopsy tool for endoscopic ultrasound-guided fine needle biopsy (EUS-FNB). Designed for gastrointestinal lesion sampling, including pancreatic cancer diagnosis, the product strengthens Olympus’ minimally invasive diagnostic portfolio.
SWOT Analysis Highlights
Cook Medical
Strength:
Cook Medical demonstrates strong innovation capabilities, particularly with its EchoTip ClearCore EUS Biopsy Needle featuring a cobalt-chromium Franseen tip. The device enhances puncture precision and tissue yield, improving diagnostic reliability. High physician satisfaction rates further reinforce its competitive position.
INRAD, Inc.
Strength:
INRAD’s “No-Throw” biopsy technology in its PreciseCore device reduces overshoot trauma by eliminating forward stylet motion during tissue sampling. The device offers ultrasound compatibility and precise depth control, positioning the company as an innovator in safety-focused biopsy solutions.
Recent Industry Developments
CONMED Corporation
CONMED completed its acquisition of In2Bones Global Inc., expanding its orthopedic portfolio. The acquisition was funded through convertible notes, credit facilities, and cash reserves.
Argon Medical Devices, Inc.
In May 2023, Argon introduced the SuperCore Advantage™ Semi-Automatic Biopsy Instrument in the U.S., designed to retrieve larger tissue samples and improve diagnostic accuracy.
Sustainability Initiatives
Stryker Corporation
Stryker aims to reduce Scope 1 and 2 greenhouse gas emissions by 20% and achieve carbon neutrality by 2030. The company is transitioning toward 100% renewable electricity globally by 2027.
B. Braun Melsungen AG
B. Braun targets a 50% reduction in Scope 1 and 2 emissions by 2030 (from a 2021 baseline). Its facilities incorporate photovoltaics, energy recovery systems, heat pumps, and renewable electricity to drive carbon-neutral production.
Comprehensive Market Coverage
The biopsy devices market report provides detailed analysis across:
- Historical Trends
- Forecast Analysis
- Market Share Analysis
- Company Analysis
- Revenue Analysis
- Product Benchmarking
- Strategic SWOT Assessments
- Sustainability Evaluations
- Mergers & Acquisitions
- Partnerships & Investments
Companies covered include:
- Cardinal Health, Inc.
- Hologic, Inc.
- Danaher Corporation
- Becton, Dickinson and Company
- Boston Scientific Corporation
- Medtronic plc
- Olympus Corporation
- CONMED Corporation
- Argon Medical Devices, Inc.
- Cook Medical
- INRAD, Inc.
- FUJIFILM Holdings Corporation
- Stryker Corporation
- Merit Medical Systems, Inc.
- B. Braun Melsungen AG
Final Thoughts
The global biopsy devices market is positioned for sustained and stable growth through 2033. With projected revenues reaching US$ 4.02 billion, the sector reflects the increasing importance of early diagnosis, precision medicine, and minimally invasive technologies.
Key competitive dynamics include:
- Integration of AI and imaging technologies
- Expansion of single-use and disposable biopsy tools
- Strategic acquisitions to strengthen portfolios
- Sustainability-driven manufacturing initiatives
- Geographic expansion into emerging healthcare markets
As healthcare systems prioritize faster, safer, and more accurate diagnostics, biopsy device manufacturers will continue to innovate at the intersection of precision, patient comfort, and technological advancement.
In an era defined by early detection and personalized treatment, biopsy devices remain a cornerstone of modern diagnostic medicine—driving better outcomes and shaping the future of patient care worldwide.
